315 results about "Streptococcus suis" patented technology

The invention relates to Streptococcus suis infection in pigs, vaccines directed against those infections and tests for diagnosing Streptococcus suis infections. The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of Streptococcus suis or a gene or gene fragment derivated thereof. The invention further provides a nucleic acid probe or primer allowing species or serotype-specific detection of Streptococcus suis. The invention also provides a Streptococcus suis antigen and vaccine derived thereof.

The invention provides a Taqman-MGB fluorescent quantitative PCR kit and a method for detecting 12 common viruses and bacteria of pigs at the same time. The kit comprises PCR reaction liquids A/B/C, wherein the PCR liquids comprise primer pairs and Taqman probes for porcine parvovirus (PPV), type-II streptococcus suis (SS-II), a porcine pseudorabies virus (PRV), type-II porcine circovirus (PCV-2), a hog cholera virus (CSFV), a pig foot and mouth disease virus (FMDV), a porcine reproductive and respiratory syndrome virus (PRRSV), a high pathogenicity porcine reproductive and respiratory syndrome virus strain (Hp-PRRSV), a transmissible gastroenteritis virus (TGEV), an epidemic diarrhea virus (PEDV), rotavirus (PRTV) and a swine influenza virus (SIV) respectively. 12 pathogens of pigs can be detected rapidly and effectively at the same time, the detection method is high in accuracy, specificity and sensitivity and is good in stability, and rapid diagnosis and effective detection on pathogens to be detected can be achieved.

The invention discloses a porcine streptococcus disease and haemophilus parasuis disease combined inactivate vaccine and a preparation method thereof. The preparation method comprises the following steps of: a, respectively carrying out enrichment culture on a porcine streptococcus strain, a haemophilus parasuis strain and a haemophilus parasuis strain to obtain a porcine streptococcus strain bacterial solution, a haemophilus parasuis strain bacterial solution and a haemophilus parasuis strain bacterial solution; b, respectively adding a formaldehyde solution into the porcine streptococcus strain bacterial solution, the haemophilus parasuis strain bacterial solution and the haemophilus parasuis strain bacterial solution, and inactivating; c, mixing the collected porcine streptococcus strain bacterial solution, the haemophilus parasuis strain bacterial solution and the haemophilus parasuis strain bacterial solution, adding Tween-80 for preparing a water phase, preparing white oil, Span-80 and aluminium stearate into an oil phase, mixing the water phase with the oil phase to prepare a uniform emulsion, i.e. an oil emulsion inactivating vaccine; and 4, sub-packaging the oil emulsion inactivating vaccine. The porcine streptococcus disease and haemophilus parasuis disease combined inactivate vaccine can effectively prevent the porcine streptococcus disease and haemophilus parasuis disease, does not have hidden danger of scattering viruses and is safe and reliable; and the immunization is realized by one vaccine, thus the cost is reduced.

The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

The invention discloses an expression method of lactococcus lactis of porcine streptococcus phage catenase in the technical field of biology. A pyrolyzed gene of porcine streptococcus virulent phage SMP is augmented by utilizing polymerase chain reaction (PCR) to obtain a target fragment which is connected with a pNZ8148 vector so as to obtain a recombined expression plasmid; lactococcus lactis L9000 expression is adopted so s to obtain a fusion protein the molecular weight of which is 52kDa, so as to obtain activated catenase which has a pyrolyzed actioin on multiple clinically separated porcine streptococcus in vitro.

The invention relates to a kit for detecting streptococcus suis type 2 nucleic acid by an isothermal nucleic acid amplification method and application of the kit to detection of streptococcus suis type 2 nucleic acid. The kit comprises amplification reaction liquid, primer reaction liquid, DNA (deoxyribonucleic acid) polymerase, nucleic acid dye, an S.suis type 2 positive standard product and a negative control product. A method for applying the kit to S.suis type 2 positive detection comprises five steps of extracting DNA of to-be-tested specimen bacteria, performing loop-mediated isothermal amplification (LAMP) on S.suis type 2 CPS2J gene, performing electrophoretic detection on an amplification product, performing chromogenic reaction of the LAMP amplification product and judging positive of S.suis type 2 streptococcus. The kit has the advantages of quickness, convenience, strong specificity and high sensitivity when being applied to positive detection of the S.suis type 2 streptococcus, and is very suitable for quick detection of the S.suis type 2 streptococcus in medical or food industry.

The present invention relates to a hemophilus parasuis disease, a swine streptococcosis bivalent inactivated vaccine and a preparation method thereof. The vaccine is prepared by adopting a hemophilus parasuis serotype 4 JS strain, a hemophilus parasuis serotype 5 ZJ strain and a streptococcus suis type 2 SC strain as antigens, and adopting a veterinarily acceptable adjuvant, concurrently provides immunoprophylaxis for hemophilus parasuis diseases caused by hemophilus parasuis, swine streptococcosis caused by streptococcus suis, and mixed infection of the hemophilus parasuis disease and the swine streptococcosis, has effects of low side effect, no endotoxin, no impurity protein in serum, good immunization safety, multi-prevention effect with one needle in the clinic, and cost reducing, and can meet different requirements of different users.

The invention discloses a trigeminy inactivated vaccine for porcine circovirus disease, porcine streptococcus suis disease and porcine haemophilus parasuis disease, a preparation method of the vaccine and applications of the vaccine. Porcine circovirus 2-WH has an accession number of CCTCC NO: V20133 and has strong virulence, good immunogenicity, a high antigen titer, and a high virulence reaching 10<7.4>TCID[50]/mL. The trigeminy inactivated vaccine, which is prepared by mixing the porcine circovirus 2-WH, porcine streptococcus suis 2-LT, and porcine haemophilus parasuis 4-MD0322 and porcine haemophilus parasuis 5-SH0165, can simultaneously prevent the porcine circovirus disease and diseases caused by porcine streptococcus suis 2-type, porcine haemophilus parasuis 4-type and porcine haemophilus parasuis 5-type, the immune protective effect on the same serotype reaches over 80%.

The invention discloses a multiple PCR detection kit for virulence factors of streptococcus suis and a detection method thereof, and belongs to the technical field of biology. The multiple PCR detection kit comprises nucleic acid shown by base sequences, such as SEQ ID NO:1 to SEQ ID NO:20. The detection method for the multiple PCR detection kit comprises the following steps of: 1, providing DNA of samples to be detected; 2, taking the kit, amplifying the DNA of the samples to be detected by adopting the conventional PCR method, detecting an amplified result by adopting an agarose gel electrophoresis method, and judging according to the result; and by using positive DNA of streptococcus suis 2 type as contrast, if the contrast proves that not all the strips are amplified, re-detecting, and if the contrast proves that all the strips are amplified, judging the result. The multiple PCR detection method established by the invention is specific and sensitive, and has the advantages of simpleness, convenience and quickness. The multiple PCR detection kit has reliable stability, and can be used for rapid detection of clinical samples and survey research on molecular epidemiology for the streptococcus suis.

The invention relates to the field of diagnosis of and vaccination against Streptococcal infections and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of Streptococcus wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof as shown in FIG. 5.

The invention provides an inactivated vaccine for streptococcus suis and pasteurella multocida diseases and a preparation method thereof, which can prevent streptococcus suis infection caused by a plurality of different sero-group streptococcus and infection caused by a plurality of different capsular serotype pasteurella multocida, achieves multiple preventions with one injection clinically, and is lowered in cost, free from the hidden hazard of virus dispersion, safe and reliable. The invention further provides a method for preparing the inactivated vaccine for streptococcus suis and pasteurella multocida diseases.

A streptococci recombined subunit vaccine for preventing the streptococcicosis of pig includes the fusion protein of the horseí»s Streptococcus equi subsp zooepidemicus type M protein fragment and the pigí»s Streptococussuis 2 type lysozyme releasing protein fragment. Said fusion protein has high immunogenicity. The gene for coding said fusion protein is also disclosed.

The invention discloses a streptococcus suis type 2 10 gene-deleted strain and application. The strain is obtained by knocking out 10 genes on the basis of a streptococcus suis type 2 virulent strain, and the preservation serial number is CCTCC NO: M 2015800. The virulence of the strain is significantly reduced compared with that of the parent strain, safety is high, immunogenicity is high, and immunized mice can be protected against the attack of the streptococcus suis type 2 virulent strain after being immunized in an injection or nasal drip or oral administration mode, which shows that the vaccine can effectively activate the mucosal immune system and systemic immunology of a host; meanwhile, a cross protection function on streptococcus suis type 2 virulent strains of different ST types can also be achieved. The vaccine is simple in preparation method and suitable for industrial production; meanwhile, the immunogenicity of the mutant strain is similar to that of a wild virulent strain, and thus the mutant strain can be applied to the development of rapid reagent kits as a standard substance or a whole-cell antigen.

The invention relates to a gene knock-out mutant of Streptococcus suis type 2 salKR and the preparation method and the application thereof. The mutant 05ZYH33 delta salKR has the preservation number of CGMCC No.2259. The preparation method comprises a step of subjecting a dual signal transduction system in PAI89K pathogenicity island on chromosome 05ZYH33 of wild S.suis 2 strain to gene knock-out by homologous recombination technology. Verified by PCR identification and Southern blotting, the obtained stain is gene knock-out mutant named as 05ZYH33 delta salKR. Animal test shows that the mutant has no harm to animals, and the whole genome sequence of the mutant has large similarity to that of the wild strain, so that the mutant is suitable for research and production of vaccines.

The triplex PCR-based rapid detection kit for Streptococcus suis Type 2 which is composed of four cryopreservation tubes containing different components, 100 PCR reaction tubes and the brochure of the detection steps for the cryopreservation tubes. The four cryopreservation tubes contain mixture of 10*buffer, dNTP, primer gdh-1, gdh-2, mrp-1, mrp-2,cps2J-1, cps2J-2 and Taq DNA polymerase; lysis buffer; positive control solution; diluent respectively. The triplex PCR process established in the present invention can amplify gene gdh, mrp and cps2J of SS-2 at the same time and has high specificity. The homology of sequencing is always between 98.84% and 100% exhibiting high accuracy and specificity.

An electrochemical immunosensor making method is characterized in that the making method comprises the following steps: modifying a glassy carbon electrode by nano-gold, washing with a buffer solution, airing, coating the surface of the glassy carbon electrode by one droplet of a Streptococcus suis type 2 antibody, staying at 4DEG C overnight, and immersing the obtained glassy carbon tube in a bovine serum albumin solution to obtain an electrochemical immunosensor. The electrochemical immunosensor has a simple making method and is convenient to use, and the electrochemical immunosensor type 2 detection method using the electrochemical immunosensor has the advantages of simplicity, easy implementation, high sensitivity, short response time, low detection cost, accurate and reliable detection result, and creation of important conditions for the diagnosis and treatment of cardiovascular diseases.

The invention relates to a haemophilus parasuis detection kit and a detection method thereof, and belongs to the technical field of molecular biology. The detection kit comprises a primer pair, PCR Mix, a position control and dd H2O. The haemophilus parasuis detection kit disclosed by the invention has the primer pair designed according to an mviN gene sequence in a high conserved domain, is good in specificity, and can accurately distinguish the haemophilus parasuis strain LC from haemophilus paragallinarum, actinobacillus pleuropneumoniae, pasteurella muhocida, arcanobacterium pyogenes, staphylococcus aureus and streptococcus suis; the detection kit and the detection method provided by the invention are high in sensitivity, short in consumed time, accurate in detection, and important in significance of monitoring haemophilus parasuis reproduction, disease occurrence and prevalence as well as timely control of the disease.

The invention relates to a novel tetravalent inactivated vaccine for streptococcus suis disease, which is prepared from a Lancefield group C streptococcus equi zooepidemicus C55138 antigen, a Lancefield group D streptococcus C55914 antigen, a Lancefield group E streptococcus C55949 antigen and a streptococcus suis type 2 HA9801 antigen by the steps of strain reproduction, bacterial liquid cultivation, pure inspection, live bacteria counting, inactivation, inactivation inspection, sedimentation and concentration, toxin removal, vaccine preparation by mixing, asepsis inspection of the vaccine, potency inspection and subpackaging. The novel tetravalent inactivated vaccine for the streptococcus suis disease can take precautions against four streptococcus suis diseases caused by Lancefield group C streptococcus, Lancefield group D streptococcus, Lancefield group E streptococcus and streptococcus suis type 2 through one-time vaccination, and has wide application prospect.

The invention provides a preparation method of a triple inactivated vaccine for pigs. The method determines an antigen composition with excellent immunization effects by selection of the antigen. The prepared polyvalent vaccine has outstanding immunization effects. The prepared vaccine contains a PCP immunization protective antigen exotoxin (Aps), has cross immunization protection effects better than those of a whole cell inactivated vaccine, greatly reduces side reaction, and can simultaneously prevent haemophilus parasuis, swine streptococcosis and actinobacillus pleuropneumonia by combined immunization with inactivated haemophilus parasuis and streptococcus suis. Compared with haemophilus parasuis and streptococcus suis inactivated vaccines sold on the market, the triple inactivated vaccine has the same corresponding pathogen immune protection force. Compared with the actinobacillus pleuropneumonia inactivated vaccine sold on the market, the triple inactivated vaccine has a cross immunization protecting force on diseased pigs with different serotypes and realizes multiple protection purposes.

The invention discloses a group of natural antimicrobial peptides derived from fungi. Amino acid sequences of the natural antimicrobial peptides are separately shown in SEQ ID NO: 3-4. Mature peptidesequences of the antimicrobial peptides are obtained through retrieving a fungal protein database and carrying out screening analysis; proven by comparative analysis, the amino acid sequences of the natural antimicrobial peptides are obviously different from those of all currently-known antimicrobial peptides, and the natural antimicrobial peptides belong to novel antimicrobial peptides. The antimicrobial peptides are optimized through codon, and then, the recombinant expression of the antimicrobial peptides can be achieved in pichia pastoris. Proven by antimicrobial experiments, the antimicrobial peptides disclosed by the invention have remarkable bacteriostasis activity to gram-positive bacteria, particularly Staphylococcus aureus ATCC43300, Streptococcus suis CVCC 3928 and CVCC 606, canbe applied to the fields of antibacterials, food additives, cosmetics, feed additives, preservatives and the like and have broad application values and market prospects.

The invention belongs to the technical fields of veterinary microbiology and zoonotic diseases, and in particular relates to application of immunogenic protein genes of streptococcus suis type-2 for separating, cloning and expressing exocellular peptides and recombinant proteins of the encoded proteins in vaccine and diagnosis. In the invention, a new immunogenic protein gene hp0245 is separated from SC-19 bacterial strains of streptococcus suis type-2 virulent strains, wherein DNA (hp0245EC) for encoding the exocellular peptides has nucleotide sequences represented in the sequence table SEQ ID No:1 and is encoded with 261 amino acids. The recombinant protein HP0245EC remains the immunogenic feature of the primitive protein, can provide effective immunological protection to the SC-19 bacterial strain of the streptococcus suis type-2 infected in mice and has potential application value of vaccine. The invention further comprises a composition and preparation method for a streptococcus suis type-2 HP0245-ELISA diagnostic reagent kit, and a preparation of hp0245EC for cloning hp0245EC escherichia coli; the recombinant escherichia coli has been preserved in the China Center for Type Culture Collection (CCTCC) and the preservation number is CCTCC No: M2010258.

The invention belongs to the technical field of biology, and relates to a bacteriostatic-activity enhanced streptococcus-suis bacteriophage elysin and a preparing method thereof.A lySMP coding area gene sequence serves as a template, and is subjected to random mutation through error-prone PCR, then PCR products are connected with pET-28a (+) to be subjected to induction expression in BL21, and elysin with activity 1.8 times that of LySMP is obtained with the 96-hole-plate screening method; the most suitable pH and the most suitable temperature of the elysin are measured through a 96 hole plate.As the elysin has the advantages that acting is rapid, resistance is not prone to generation, and the elysin has the synergic sterilization effect with other antibiotics, the elysin is a potential bactericide; the effect of the elysin as the effective bactericide on resisting to the streptococcus-suis infection can be further researched through the obtained elysin, and contribution can be made in the control aspect of streptococcus suis.